A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Human papillomavirus vaccine recombinant 9 valent Shanghai Zerun Biotechnology (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Shanghai Zerun Biotechnology Co
Most Recent Events
- 20 Oct 2022 New trial record